BBI-940 + Fulvestrant
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer
Trial Timeline
Feb 25, 2026 → May 31, 2029
NCT ID
NCT07408089About BBI-940 + Fulvestrant
BBI-940 + Fulvestrant is a phase 1 stage product being developed by Boundless Bio for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07408089. Target conditions include Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07408089 | Phase 1 | Recruiting |
Competing Products
20 competing products in Breast Cancer